My Web Dashboard





SEO News: Merck Serono Announces Presentation of Phase III Clinical Data on Safinamide in Parkinson's Disease at the American ... (FinanzNachrichten)

GENEVA, Switzerland, April 27 /PRNewswire/ -- Merck Serono S.A. ( Nachrichten ) (virt-x: SEO) and its partner Newron Pharmaceuticals S.p.A. (SWX: NWRN) announced today that Professor Fabrizio Stocchi, MD, PhD, will present the results of the first Phase III trial of safinamide as an adjunctive treatment to dopamine agonists (DA) in early Parkinson's disease (PD) patients at the American Academy ...

read more...

Related News